CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Testosterone undecanoatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00911586
NCT00911586Phase 2Completed
CompareCT.gov

Pharmacokinetic Study to Determine Time to Steady-state of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men.

Clarus Therapeutics, Inc.·interventional·Posted Jun 2, 2009·Updated Dec 11, 2020

In Brief

A Phase 2 clinical trial evaluating Testosterone undecanoate for Male Hypogonadism and 2 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2, 2009
Enrollment StartJul 1, 2009
Primary CompletionSep 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.1 years ago

Interventions

Testosterone undecanoatedrug